Project Area — Technology Transfer
Success Cases — Service Quality Proof
Documented outcomes across patent licensing, OEM commercialization, and investor communication — aligned with our mandate at the intersection of Research, Biotech, and Finance.
Biotech Licensing
University Biotech Patent Licensing — Executed on Favourable Commercial Terms
HCCT Group has successfully facilitated the negotiation and execution of exclusive licensing agreements for university-originated biotech patents, securing commercially advantageous terms on behalf of our clients.
- Conducted comprehensive due diligence on patent claims, freedom-to-operate landscape, and regulatory classification in advance of term-sheet negotiation.
- Structured licensing frameworks inclusive of upfront licence fees, milestone-contingent royalty schedules, sub-licensing rights, and field-of-use restrictions aligned with the licensee's downstream commercialization strategy.
- Established and maintained an active engagement network spanning multiple Technology Transfer Offices (TTOs) in Hong Kong — including HKU, CUHK, CityU, and HKUST affiliated centres — enabling direct facilitation between institutional IP holders and commercially motivated licensees.
- Coordinated tripartite discussions between relevant academic research groups, industry counterparties, and investment stakeholders, ensuring alignment of scientific, legal, and commercial objectives throughout the licensing lifecycle.
Outcome: Licensing agreements executed with materially favourable royalty structures and retained sub-licensing optionality, enabling downstream commercialization without undue IP encumbrance.
Patent Commercialization
Licensed Patent Commercialization — Downstream Service Integration & OEM Production Deployment
HCCT Group brings demonstrable operational experience in translating licensed patent rights into revenue-generating commercial outputs through downstream service delivery and OEM-based manufacturing deployment.
- Managed end-to-end commercialization of licensed biotech and advanced-materials patents, including technical feasibility validation, regulatory pathway scoping, and production readiness assessment.
- Leveraged an extensive OEM manufacturing network to identify qualified contract manufacturers capable of meeting both technical specifications and commercial scale requirements within acceptable unit economics.
- Developed detailed manufacturing process estimations including bill-of-materials modelling, yield analysis, cost-per-unit projections, and minimum viable batch sizing to underpin investor and partner due diligence.
- Structured commercial agreements governing production rights, quality assurance obligations, exclusivity provisions, and revenue-sharing arrangements between patent licensors, manufacturers, and distribution partners.
Outcome: Successful integration of licensed IP into production-ready commercial frameworks, with OEM partners formally engaged and downstream service revenue models validated against market-acceptable cost structures.
Investor Communication
Research Investment Optimisation — Improving Capital Efficiency and Demonstrable ROI Against Development Timelines
HCCT Group provides structured advisory support to research-intensive organisations seeking to improve the measurable return on research investment, rationalise capital deployment, and accelerate value-creation timelines.
- Established quantitative frameworks linking research expenditure to projected output metrics — including publication output, IP generation, prototype readiness, and regulatory milestone achievement — across standardised development timelines.
- Identified and eliminated structural inefficiencies in research budget allocation through milestone-gated funding models, reducing non-productive expenditure whilst preserving scientific programme integrity.
- Prepared investor-grade communication materials — inclusive of financial models, sensitivity analyses, and capital efficiency benchmarking — designed to satisfy institutional due diligence requirements and support funding committee presentations.
- Aligned research roadmaps with investor return expectations by establishing clear value inflection points, defining exit-proximate milestones, and quantifying projected ROI under base, upside, and downside scenarios.
Outcome: Demonstrated improvement in research capital efficiency, with clients reporting more disciplined milestone sequencing, stronger investor confidence, and materially improved ROI clarity within standard development timelines.
Discuss your commercialization mandate with HCCT Group
Specialised in Patent Commercialization and Funding Pathway — Hong Kong & international markets.